Summary
The performance of OLX-209 indicates it should enter phase I clinical testing. OLX-209 is a recombinant toxin targeting theerbB-2 oncoprotein. The design of OLX-209 takes advantage of improvements in immunotoxin technology to produce a molecule that is smaller and more potent than a conventional chemically linked antibody-toxin conjugate. The targeting portion of OLX-209 is a single chain antibody structure derived from the anti-erbB-2 hybridoma, e23. This antibody has unusual specificity in that it does not bind to most normal tissue including peripheral nerve or kidney tissue.
Preclinical testing showsin vitro activity against breast cancer cell lines in the pM range. Efficacy testing in five models of human cancer indicates that a dose of 43 µg/kg causes reproducible tumor regressions. Efficacy can be achieved on a variety of schedules of administration. The effective dose results in no measurable change in serum liver enzymes when delivered to mice or primates. The LD10 is over twice the effective dose in mice. The pharmacokinetics indicate a t1/2 of 50 minutes for both mice and cynomolgus monkeys. Serum concentrations of more than ten times those observed at the effective dose can be achieved in monkeys with no evidence of toxicity. Antigenicity of OLX-209 is surprisingly low. These results form the basis for the clinical testing phase for OLX-209.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
King CR, Kraus MH, Aaronson SA: Amplification of a novel v-erbB related gene in a human mammary carcinoma. Science 229:974–976, 1985
Semba K, Kamata N, Toyoshima K, Yamamoto T: A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor receptor gene and is amplified in a human salivary gland adenocarcinoma. Proc Natl Acad Sci USA 82:6497–6501, 1985
Bargmann CI, Hung MC, Weinberg RA: Theneu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319:226–230, 1986
Kraus MH, Popescu NC, Amsbaugh C, King CR: Overexpression of the EGF receptor-related protooncogeneerbB-2 in human mammary tumor cell lines by different molecular mechanisms. EMBO J 6:605–610, 1987
Schneider PM, Hung M-C, Chiocca SM, Manning J, Zhao XY, Fang K, Roth JA: Differential expression of theerbB-2 gene in human small cell and non-small cell lung cancer. Cancer Res 49:4968–4971, 1989
Akiyama T, Sudo C, Ogawara H, Toyoshima K, Yamamoto T: The product of the c-erbB-2 gene: A 185 kd phosphoprotein with tyrosine kinase activity. Science 232:1644–1646, 1986
DiFiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA:erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178–182, 1986
Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p 185 (HER2) causes transformation and tumorigenesis of NIH/3T3 cells. Proc Natl Acad Sci USA 84:7159–7163, 1987
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–182, 1987
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF: Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244:707–712, 1989
Berger MS, Locher GW, Saurer S, Gullick WJ, Waterfield MD, Grover B, Hynes NE: Correlation of c-erbB-2 gene amplification and protein expression in human breast cancer with nodal status and nuclear grading. Cancer Res 48:1238–1243, 1988
Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathological findings from the National Surgical Adjuvant Breast and Bowel Project: prognostic significance oferbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112, 1990
Kern JA, Schwartz DA, Nordberg JE, Weinberg DB, Greene MI, Tormey L, Robinson RA: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184–5191, 1990
Pastan I, FitzGerald DJP: Recombinant toxins for cancer treatment. Science 254:1173–1177, 1991
Bird RE, Hardman KD, Jacobson JW, Johnson S, Kaufman BM, Lee S-M, Lee T, Pope SH, Riordan GS, Whitlow M: Single chain antigen binding proteins. Science 242:423–426, 1988
Batra JK, Kasprzyk PG, Bird RE, Pastan I, King CR: Recombinant anti-erbB-2 immunotoxins containingPseudomonas exotoxin. Proc Natl Acad Sci USA 89:5867–5871, 1992
Kasprzyk PG, Song SV, DiFiore PP, King CR: Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer Research 51:2771–2776, 1992
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
King, C.R., Kasprzyk, P.G., Fischer, P.H. et al. Preclinical testing of an anti-erbB-2 recombinant toxin. Breast Cancer Res Tr 38, 19–25 (1996). https://doi.org/10.1007/BF01803780
Issue Date:
DOI: https://doi.org/10.1007/BF01803780